Scientific Publications

Advancing dermatological science.

May 2025 Featured

JAMA Dermatology

Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body The ARRECTOR Phase 3 Randomized Clinical Trial

September 2024 Featured

JAMA Dermatology

Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials

March 2023 Featured

AAD 2023

Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial: Assessment of Pruritus

December 2025

J Clin Aesthet Dermatol

PDE4 Inhibitor-Responsive Dermatoses: An Emerging Concept in Dermatology

November 2025

American Journal of Clinical Dermatology

Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks

August 2025

Pediatric Dermatology

Early evidence of safety, clinical benefit, and PK of roflumilast cream 0.3% once daily in children 2–11 (psoriasis)

February 2025

Pediatric Dermatology

Efficacy and safety of once-daily roflumilast cream 0.05% in pediatric AD age 2–5 (INTEGUMENT-PED)

January 2025

Dermatitis

Long-term safety & efficacy with roflumilast cream 0.15% (≥6y, open-label extension)

November 2024

J Invest Dermatol

Chemical, biochemical, and structural similarities/differences of dermatological cAMP PDE-IV inhibitors

October 2024

Dermatology and Therapy

Patient and Healthcare Provider Perspectives on Disease Burden of Seborrheic Dermatitis in the United States: Results from a National Survey

October 2024

Journal of Drugs in Dermatology

Assessment of the Vehicle for Roflumilast Cream Compared to a Ceramide-Containing Moisturizing Cream in Mild Eczema

September 2024

Advances in Therapy

Patient and Healthcare Provider Perspectives on the Pathway to Diagnosis of Seborrheic Dermatitis in the United States

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download